Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan.
Hum Vaccin Immunother. 2012 Sep;8(9):1309-13. doi: 10.4161/hv.20988. Epub 2012 Aug 16.
Since both tumor cells and immune cell repertoires are diverse and heterogeneous, immune responses against tumor-associated antigens might be substantially different among individual patients. Personalized selection of right peptides for individuals could thus be an appropriate strategy for cancer vaccines. We have developed a novel immunotherapeutic approach, personalized peptide vaccination (PPV), in which HLA-matched peptides are selected and administered, based on the pre-existing host immunity before vaccination. Recent clinical trials of PPV have demonstrated a feasibility of this new therapeutic approach in various types of advanced cancers. For example, a randomized phase II trial for patients with castration resistant prostate cancer showed a possible clinical benefit in the PPV group. In the patients undergoing PPV, lymphocyte counts, increased IgG responses to the vaccine peptides, and inflammatory factors in pre-vaccination peripheral blood might be potential biomarkers for prognosis. Further randomized phase III trials would be recommended to prove clinical benefits of PPV.
由于肿瘤细胞和免疫细胞的多样性和异质性，针对肿瘤相关抗原的免疫反应在个体患者之间可能有很大的不同。因此，为个体选择合适的肽类可能是癌症疫苗的一种恰当策略。我们开发了一种新的免疫治疗方法，即个体化肽疫苗接种（PPV），该方法基于接种前的宿主预先存在的免疫，选择和给予与 HLA 匹配的肽。最近的 PPV 临床试验已经证明了这种新治疗方法在各种晚期癌症中的可行性。例如，一项针对去势抵抗性前列腺癌患者的随机 II 期试验显示，PPV 组可能有临床获益。在接受 PPV 的患者中，淋巴细胞计数、针对疫苗肽的 IgG 反应增加以及接种前外周血中的炎症因子可能是预后的潜在生物标志物。还建议进行进一步的随机 III 期试验来证明 PPV 的临床获益。
